Compare HOFT & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOFT | MNOV |
|---|---|---|
| Founded | 1924 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.7M | 137.8M |
| IPO Year | 1999 | 2004 |
| Metric | HOFT | MNOV |
|---|---|---|
| Price | $13.02 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 42.2K | ★ 729.7K |
| Earning Date | 04-16-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | $17.37 | N/A |
| Revenue Next Year | $9.00 | $180.00 |
| P/E Ratio | $52.56 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $8.62 | $1.17 |
| 52 Week High | $18.09 | $3.90 |
| Indicator | HOFT | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 43.17 |
| Support Level | $12.03 | $1.28 |
| Resistance Level | $13.71 | $3.90 |
| Average True Range (ATR) | 0.65 | 0.35 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 37.52 | 4.98 |
Hooker Furnishings Corp is a designer, marketer, and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality, and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segments: Hooker Branded segment, Domestic Upholstery segment, and All Other. It generates the majority of its revenue from the Hooker Branded segment.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.